IP Library Granted Patent US 10,080,779
Granted Patent B2
US 10,080,779 · App. 14/500,373 · Granted Sep 25, 2018

Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM

Inventors: Jean-Claude Lecron (Bonnes, FR); Hughes Gascan (Angers, FR); Franck Morel (Savigney l'Evescault, FR); Sylvie Chevalier (Angers, FR); Francois-Xavier Bernard (Saint Maurice la Clouere, FR); Katia Boniface (Mountain View, CA); Caroline Diveau (Palo Alto, CA)
Assignees: Universite D'Angers; Universite de Poitiers; Bioalternatives SAS
A61K38/2006A61K8/64A61K38/1793A61K38/20A61K38/204A61K38/217A61Q19/00C07K16/28C12N5/0629C07K2317/76C12N2501/2306
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,080,779
App. No.
14/500,373
Granted
Sep 25, 2018
Kind
B2
Abstract

The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNFα and OSM that can be formulated for topical administration for cosmetic or dermatologic use.

Claims (7)

1. A method for stimulating an increase in the expression of anti-microbial peptides selected from the group consisting of cathelicidins, defensins, SI00 calcium-binding proteins, Wey Acidic Protein Four-Disulfide Core Domain proteins (WFDC) and RNAse 7, by keratinocytes in vitro by culturing said keratinocytes in presence with a composition comprising IL-17, TNFα and Oncostatin M (OSM) or in vivo by contacting said keratinocytes topically or intradermally in a subject suffering from acne, atopic dermatitis, eczema, seborrheic dermatitis, erythema, eschar, skin ulcers, ichtyosis, bullous epidermolysis, malum perforans pedis, wart, with an effective amount of a composition comprising IL-17, TNFα and Oncostatin M (OSM), said expression of anti-microbial peptides being increased in comparison with unstimulated keratinocytes.

2. The method according to claim 1 , wherein said anti-microbial peptides are chosen from:

cathelicidin LL37,

beta-defensin 2 and beta-defensin 3,

S100 calcium-binding protein A7, S100 calcium-binding protein A7A, S100 calcium-binding protein A8, S100 calcium-binding protein A9, S100 calcium-binding protein A12,

Wey Acidic Protein Four-Disulfide Core Domain protein (WFDC5) and Wey Acidic Protein Four-Disulfide Core Domain protein 12 (WFDC12), and

RNAse 7.

Priority Claims (1)
EP 04293004 · Dec 15, 2004 · regional
Continuity (3)
Continuation In Part 13283508 · Oct 27, 2011
Division 11721763
Related Publication 20150086508A1 · Mar 26, 2015